180 Life Sciences (ATNF) Competitors $0.89 -0.01 (-0.66%) Closing price 07/15/2025 03:47 PM EasternExtended Trading$0.89 0.00 (-0.12%) As of 07/15/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATNF vs. DARE, FNCH, RLMD, SLGL, DRRX, MIRA, NAII, BCTX, LGVN, and JATTShould you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include Dare Bioscience (DARE), Finch Therapeutics Group (FNCH), Relmada Therapeutics (RLMD), Sol-Gel Technologies (SLGL), DURECT (DRRX), MIRA Pharmaceuticals (MIRA), Natural Alternatives International (NAII), Briacell Therap (BCTX), Longeveron (LGVN), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry. 180 Life Sciences vs. Its Competitors Dare Bioscience Finch Therapeutics Group Relmada Therapeutics Sol-Gel Technologies DURECT MIRA Pharmaceuticals Natural Alternatives International Briacell Therap Longeveron JATT Acquisition Dare Bioscience (NASDAQ:DARE) and 180 Life Sciences (NASDAQ:ATNF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings. Which has stronger valuation & earnings, DARE or ATNF? Dare Bioscience has higher revenue and earnings than 180 Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDare Bioscience$10K2,513.40-$4.05M-$0.17-16.71180 Life SciencesN/AN/A-$6.17MN/AN/A Is DARE or ATNF more profitable? Dare Bioscience's return on equity of 0.00% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Dare BioscienceN/A N/A -8.14% 180 Life Sciences N/A -147.34%-77.00% Which has more risk and volatility, DARE or ATNF? Dare Bioscience has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, 180 Life Sciences has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Does the media refer more to DARE or ATNF? In the previous week, Dare Bioscience had 4 more articles in the media than 180 Life Sciences. MarketBeat recorded 7 mentions for Dare Bioscience and 3 mentions for 180 Life Sciences. Dare Bioscience's average media sentiment score of 0.83 beat 180 Life Sciences' score of 0.63 indicating that Dare Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 180 Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in DARE or ATNF? 6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 4.1% of 180 Life Sciences shares are owned by institutional investors. 4.0% of Dare Bioscience shares are owned by company insiders. Comparatively, 38.2% of 180 Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts recommend DARE or ATNF? Dare Bioscience presently has a consensus target price of $12.00, indicating a potential upside of 322.54%. Given Dare Bioscience's stronger consensus rating and higher possible upside, equities research analysts plainly believe Dare Bioscience is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryDare Bioscience beats 180 Life Sciences on 11 of the 13 factors compared between the two stocks. Get 180 Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATNF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNF vs. The Competition Export to ExcelMetric180 Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.44M$2.96B$5.62B$9.30BDividend YieldN/A2.43%4.25%4.03%P/E Ratio-0.0620.2228.5719.58Price / SalesN/A291.25423.3093.84Price / CashN/A43.1536.0257.93Price / Book0.317.568.135.54Net Income-$6.17M-$55.11M$3.24B$257.73M7 Day Performance6.35%3.81%0.16%-0.08%1 Month Performance-6.86%11.60%5.95%8.09%1 Year Performance-61.46%-2.11%26.09%13.02% 180 Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNF180 Life Sciences0.8337 of 5 stars$0.89-0.7%N/A-56.0%$5.44MN/A-0.067News CoverageDAREDare Bioscience1.8551 of 5 stars$2.40flat$12.00+400.0%-15.7%$21.24M$10K-14.1230News CoverageHigh Trading VolumeFNCHFinch Therapeutics Group0.7724 of 5 stars$13.00-0.6%N/A+707.0%$21.00MN/A-1.47190Positive NewsRLMDRelmada Therapeutics4.7417 of 5 stars$0.61-3.1%$5.00+719.4%-83.5%$20.91MN/A-0.2410Gap DownSLGLSol-Gel Technologies3.1757 of 5 stars$7.29-2.4%$40.00+448.7%-9.9%$20.80M$11.54M-1.5550Gap DownDRRXDURECT1.2059 of 5 stars$0.64-4.0%N/A-60.7%$20.70M$1.86M-4.2780Positive NewsGap DownHigh Trading VolumeMIRAMIRA Pharmaceuticals2.4242 of 5 stars$1.15-4.2%$14.00+1,117.4%+124.3%$20.30MN/A-2.252NAIINatural Alternatives International1.4625 of 5 stars$3.32+2.2%N/A-39.3%$20.08M$125.48M-2.39290BCTXBriacell Therap1.8802 of 5 stars$2.89-0.7%$32.00+1,007.3%-94.5%$19.72MN/A-0.358Gap DownLGVNLongeveron3.1661 of 5 stars$1.29-1.5%$8.67+571.8%-62.8%$19.56M$2.39M-0.2120JATTJATT AcquisitionN/A$1.13+0.9%N/A-84.1%$19.49MN/A0.003High Trading Volume Related Companies and Tools Related Companies DARE Competitors FNCH Competitors RLMD Competitors SLGL Competitors DRRX Competitors MIRA Competitors NAII Competitors BCTX Competitors LGVN Competitors JATT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATNF) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share 180 Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATNF Stock Alerts